Literature DB >> 7987864

The fate of antibodies and their radiolabels bound to tumor cells in vitro: the effect of cross-linking at the cell surface and of anti-idiotype antibodies.

G L Ong1, V Marria, M J Mattes.   

Abstract

In order to obtain rapid blood clearance of circulating antibodies (Ab) at a desired time, cross-linking reagents such as second Ab are often employed. Such reagents will generally bind to Ab located at the tumor site as well as free Ab, and we therefore investigated whether the cross-linking of Ab bound to the surface of tumor cells affects the processing of those Ab. Cross-linking was induced in various ways: a polyclonal second Ab [rabbit anti-(mouse IgG)], a monoclonal rat anti-(mouse IgG constant region) Ab, and streptavidin used in conjunction with a biotinylated first Ab. Processing was followed for 3 days, to allow nearly all of the bound Ab to reach its ultimate fate. Results depended strongly on the particular first Ab used. Two basic effects were observed. First, the second Ab efficiently prevented the early dissociation of intact Ab from the cell; once the second Ab bound, there was virtually no dissociation of the primary Ab bound to the cells. For most Ab, where only a small proportion of bound Ab dissociated intact, this effect was relatively small. However, for an unusual Ab, where the majority dissociated intact (L6) the effect of a second Ab in prolonging Ab retention by the cell was dramatic. Second, cross-linking sometimes resulted in markedly accelerated internalization and degradation of the bound Ab, coupled with the release of degradation products into the medium. This process resulted in much shorter retention of the radioisotope by the cell. If a "residualizing" radiolabel was used, 125I-dilactitoltyramine, which is probably trapped within lysosomes after Ab catabolism, the effect of the second Ab in accelerating loss from the cell was largely prevented. We also tested anti-idiotype Ab as cross-linking reagents. In addition to testing anti-idiotype Ab known to react with the cell-bound primary Ab, we also tested anti-idiotype Ab not expected to bind to cell-bound Ab, initially as a negative control. Unexpectedly, all anti-idiotype Ab tested induced rapid release of the primary Ab from the cell. This effect was similar to the effect of a large excess of unlabeled Ab, and we attribute it to the blocking of the free binding site of a "wobbling" Ab, which prevents its rebinding to a second antigen molecule. We conclude that the use of selected anti-idiotype Ab to clear circulating Ab, while not reacting with cell-bound Ab, must be done cautiously.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7987864     DOI: 10.1007/BF01519986

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Plasmapheresis in radioimmunotherapy of micrometastases: a mathematical modeling and dosimetrical analysis.

Authors:  G Sgouros
Journal:  J Nucl Med       Date:  1992-12       Impact factor: 10.057

Review 2.  Epibody: the image of the network created by a single antibody.

Authors:  C A Bona; C Y Kang; H Kohler; M Monestier
Journal:  Immunol Rev       Date:  1986-04       Impact factor: 12.988

3.  Reduction by anti-antibody administration of the radiotoxicity associated with 131I-labeled antibody to carcinoembryonic antigen in cancer radioimmunotherapy.

Authors:  R D Blumenthal; R M Sharkey; D Snyder; D M Goldenberg
Journal:  J Natl Cancer Inst       Date:  1989-02-01       Impact factor: 13.506

Review 4.  Membrane and cytoplasmic changes in B lymphocytes induced by ligand-surface immunoglobulin interaction.

Authors:  G F Schreiner; E R Unanue
Journal:  Adv Immunol       Date:  1976       Impact factor: 3.543

5.  Enhanced clearance of radiolabeled murine monoclonal antibody by a syngeneic anti-idiotype antibody in tumor-bearing nude mice.

Authors:  R M Sharkey; O C Boerman; A Natale; D Pawlyk; M Monestier; M J Losman; D M Goldenberg
Journal:  Int J Cancer       Date:  1992-05-08       Impact factor: 7.396

6.  Evaluation of monoclonal idiotypic-specific antibodies as clearing antibodies for enhancement of target localisation by tumour-specific monoclonal antibodies: diversity of effects in nude mice with human tumour xenografts.

Authors:  M V Pimm; S J Gribben
Journal:  Eur J Nucl Med       Date:  1992

7.  Processing of antibody-radioisotope conjugates after binding to the surface of tumor cells.

Authors:  M J Mattes; G L Griffiths; H Diril; D M Goldenberg; G L Ong; L B Shih
Journal:  Cancer       Date:  1994-02-01       Impact factor: 6.860

8.  The processing and fate of antibodies and their radiolabels bound to the surface of tumor cells in vitro: a comparison of nine radiolabels.

Authors:  L B Shih; S R Thorpe; G L Griffiths; H Diril; G L Ong; H J Hansen; D M Goldenberg; M J Mattes
Journal:  J Nucl Med       Date:  1994-05       Impact factor: 10.057

9.  Three-step monoclonal antibody tumor targeting in carcinoembryonic antigen-positive patients.

Authors:  G Paganelli; P Magnani; F Zito; E Villa; F Sudati; L Lopalco; C Rossetti; M Malcovati; F Chiolerio; E Seccamani
Journal:  Cancer Res       Date:  1991-11-01       Impact factor: 12.701

10.  Intratumoral generation of 5-fluorouracil mediated by an antibody-cytosine deaminase conjugate in combination with 5-fluorocytosine.

Authors:  P M Wallace; J F MacMaster; V F Smith; D E Kerr; P D Senter; W L Cosand
Journal:  Cancer Res       Date:  1994-05-15       Impact factor: 12.701

View more
  1 in total

1.  Design of high avidity and low affinity antibodies for in situ control of antibody drug conjugate targeting.

Authors:  Reginald Evans; Greg M Thurber
Journal:  Sci Rep       Date:  2022-05-10       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.